Intas Pharmaceuticals launches Intacept

Our Bureau Ahmedabad | Updated on March 27, 2015 Published on March 27, 2015


Intas Pharmaceuticals informed that the company has launched Intacept - a biosimilar to Amgen's Enbrel (entanercept) in the strengths of 25mg in 0.5 ml and 50mg in 1.0 ml preservative free solution in pre-filled syringes.

Etanercept is indicated for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Plaque Psoriasis all debilitating autoimmune diseases, the company stated.

Commenting on the launch, Binish Chudgar, vice-chairman, Intas said, "Etanercept is a fusion protein that is difficult to develop. Intacept is a further validation of our world-class R&D and manufacturing capabilities that bring global healthcare standards to Indian patients at a lower cost. Through Intacept, we are able to reduce the cost of treatment for patients to about half of the imported Enbrel."

Published on March 27, 2015
This article is closed for comments.
Please Email the Editor